GlobeNewswire Inc | Dec 20, 2021 07:00AM EST

December 20, 2021

CUPERTINO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (Reviva or the Company), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings. Please see additional details below:

11th Annual LifeSci Partners Corporate Access EventWednesday, January 5th - Friday, January 7thRegistration LinkTo submit one-on-one meeting requests Click Here

H.C. Wainwright BioConnect Virtual ConferenceMonday, January 10th - Wednesday, January 13thRegistration LinkA webcast will be available for 90 days on the Events & Presentations section of the Reviva website on January 10th at 7am ET or by using the following link: https://journey.ct.events/view/60fae5e9-6fa6-4ddb-bec0-abaff8a708f6

If you are interested in arranging a one-on-one meeting, please contact your conference representative.

About RevivaRevivais a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Revivas current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Revivas pipeline currently includes two drug candidates,RP5063(brilaroxazine) andRP1208. Both are new chemical entities discovered in-house.Revivahas been granted composition of matter patents for bothRP5063and R1208 inthe United States(U.S.),Europe, and several other countries.

Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Companys product development, clinical and regulatory timelines and expenses, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and managements current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, expect, anticipate, intend, plan, believe, estimate, potential, predict, project, should, would and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Companys filings with theSecurities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corporate Contact:Reviva Pharmaceuticals Holdings, Inc.Laxminarayan Bhat, PhD www.revivapharma.com

Investor Relations Contact:LifeSci Advisors, LLCBruce Macklebmackle@lifesciadvisors.com